Diuretic Use in Acute Kidney Injury

Introduction to Diuretic Use

• The KDIGO guidelines provide a Level 1B recommendation against using diuretics to prevent AKI, based on randomized controlled trials and meta-analyses demonstrating that furosemide does not prevent AKI and may actually increase mortality 1, 2
• Diuretics should not be used to treat AKI except for managing volume overload (Level 2C recommendation) 1, 2

Evidence Against Diuretic Use

• Furosemide is associated with worsening renal function, with studies showing patients who developed worsening renal function received a 60 mg greater total daily dose of furosemide (199 mg vs 143 mg) compared to those without deterioration 3, 4

Appropriate Diuretic Use

• Diuretics should only be used in hemodynamically stable patients with AKI who have documented volume overload 1, 4
• In patients with volume overload, furosemide may facilitate appropriate fluid balance, and higher furosemide doses had a protective effect on mortality specifically in AKI patients with volume overload 1

Special Populations

• The EASL guidelines recommend discontinuing diuretics immediately if severe hyponatremia, AKI, worsening hepatic encephalopathy, or incapacitating muscle cramps develop in cirrhotic patients 5, 6
• The International Club of Ascites recommends withdrawing all diuretics as a first-line management step for cirrhotic patients with AKI stage 1 4

Monitoring and Contraindications

• During IV diuretic therapy, monitor hourly urine output, daily renal function, and electrolytes every 12-24 hours 4
• Combining furosemide with other nephrotoxic medications increases AKI odds by 53% per nephrotoxin 4
• The KASL guidelines warn that in cirrhotic patients, diuretics should be used in the smallest effective dose once ascites is controlled to prevent complications 7

Common Pitfalls

• Never use diuretics to convert oliguric to non-oliguric AKI—this practice lacks evidence of benefit and may cause harm 4

Furosemide Use in Acute Kidney Injury

Patient Selection

• In patients with acute kidney injury (AKI), furosemide should be withheld in situations such as renal failure defined as dialysis dependence, oliguria with serum creatinine >3 mg/dL, oliguria with serum creatinine 0-3 mg/dL with urinary indices indicative of acute renal failure, and until 12 hours after last fluid bolus or vasopressor given, as recommended by Intensive Care Medicine 8
• The Society of Critical Care Medicine implies that furosemide may be considered in hemodynamically stable patients with AKI who have documented volume overload, although this specific guideline is not directly cited, a similar recommendation is made for ARDS patients without shock, where furosemide is recommended for patients with CVP >8 mmHg and adequate urine output, after ensuring mean arterial pressure ≥60 mmHg and off vasopressors ≥12 hours, as stated in Intensive Care Medicine 8

Monitoring and Management

• When furosemide must be used for volume overload in stable AKI patients, reassess volume status after administration, as recommended by Intensive Care Medicine 8

Role of Furosemide in Oliguric AKI

Critical Pitfalls to Avoid

• The Kidney International guidelines recommend never using furosemide to "reverse" established AKI, as this results in inappropriate attempts that lead to fluid overload and worsening kidney function 9, 10
• The Kidney International guidelines also recommend recognizing that oliguria has multiple etiologies beyond hypovolemia, including acute compensated hypovolemia where volume replacement (not diuresis) may be appropriate 9, 10
• The Kidney International guidelines advise against assuming early renal injury signifies need for diuresis—biomarker-positive states do not automatically indicate volume overload requiring treatment 9
• In heart failure patients with pulmonary edema, aggressive diuretic monotherapy is unlikely to prevent endotracheal intubation compared to aggressive nitrate therapy, and may transiently worsen hemodynamics, according to the Annals of Emergency Medicine 11

Furosemide Use in Acute Kidney Injury

Introduction to Furosemide-Associated Risks

• The combination of furosemide with other nephrotoxic medications increases the odds of acute kidney injury by 53% per nephrotoxin, as noted by the interaction between furosemide and other medications 12
• The European Society of Cardiology identifies loop diuretics, such as furosemide, as potentially inappropriate medications in people ≥75 years for ankle edema without heart failure or as first-line hypertension therapy, highlighting the need for cautious use in elderly patients 13, 14

Special Considerations for Patient Populations

• In patients with hypoproteinemia, such as those with nephrotic syndrome, the effect of furosemide may be weakened and its ototoxicity potentiated, requiring careful management and monitoring 13, 14
• Loop diuretics show reduced diuretic response when creatinine clearance <30 mL/min because of impaired tubular secretion, which is crucial for patients with pre-existing chronic kidney disease 13, 14

Management of Torsemide in Acute Kidney Injury

Decision‑Making Based on Volume Status and Hemodynamic Stability

• Discontinue torsemide immediately in patients who are euvolemic or hypovolemic, or who exhibit hemodynamic instability (e.g., hypotension or need for vasopressors). Continue the drug only if the patient remains hemodynamically stable (MAP ≥ 60 mmHg, off vasopressors ≥ 12 h) and has documented volume overload (pulmonary edema, peripheral edema, elevated CVP). 15
• When AKI is potentially caused by torsemide and the drug is non‑essential, the ADQI consensus recommends immediate discontinuation. A less nephrotoxic alternative should be used whenever feasible. [15][16]

Risks Associated with Polypharmacy Nephrotoxicity

• Each additional concurrent nephrotoxin (e.g., NSAIDs, aminoglycosides, ACE inhibitors, contrast media) raises the risk of AKI by approximately 53 %; therefore, torsemide should be stopped promptly in patients receiving multiple nephrotoxic agents. 15

Situations Where Torsemide May Be Continued (Reduced Dose)

• Torsemide can be maintained at a reduced dose when life‑threatening volume overload persists (severe pulmonary edema or anasarca) and the AKI trajectory is stable or improving, with stable hemodynamic parameters. 15

Monitoring Requirements When Torsemide Is Continued

*Monitoring schedule is supported by the ADQI consensus and the British Journal of Pharmacology. [15][16]17

Recommendations Against Using Loop Diuretics to Prevent or “Reverse” AKI

• The KDIGO guidelines issue a Level 1B recommendation that loop diuretics should not be used to prevent AKI; evidence shows furosemide (and by extension other loop diuretics) does not prevent AKI and may increase mortality. 18
• Torsemide should never be employed with the intent to “reverse” AKI, as diuretics do not improve renal outcomes and can be harmful. 18

Dosing Considerations in Special Populations

• Hypoproteinemic (nephrotic) patients: Torsemide’s diuretic effect may be attenuated while ototoxicity risk is heightened; careful dose titration and close monitoring are required. 15

Evidence Quality and Guideline Framework

• The ADQI 16 Workgroup consensus (2017) provides the most comprehensive expert‑based framework for managing nephrotoxins, including torsemide, in AKI. This consensus is regarded as expert opinion (high‑level guidance). [15][16]
• KDIGO’s Level 1B recommendation against preventive use of loop diuretics is based on moderate‑quality evidence from randomized trials. 18